| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
When you have an illness, you begin to learn a whole new language when it comes to taking responsibility for your health. Your physical triggers like (cardiovascular disease, high blood pressure, leaky gut, IBS, TSH, fibromyalgia, Type II Diabetes, hypothyroidism, dementia, autism, Parkinson’s, bipolar, autism, schizophrenia, colon, rectal and breast cancers), take center stage in your search for wellness. If you’re not sure if you have MTHFR Gene Mutation, but you have symptoms, you can order the test through your doctor. Most insurance will cover some of the expense. Other options will require you to create a user login: MTHFR Support, dnalife Spectracell Labs, Quest Diagnostics and Lab Corp.
Quest Diagnostics (DGX), a leading provider of diagnostic information services, today announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, the largest precision medicine trial of its kind. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Tumor gene testing by a designated lab is the only pathway for patients to enroll.
Sonora Quest Laboratories, Arizona’s leading provider of diagnostic information services, is pleased to welcome Sonya Engle as Chief Operations Officer. An executive with extensive experience leading laboratory testing, program expansion and strategic relationship management initiatives, Engle will head Sonora Quest's laboratory and technical operations.[CR-LF][CR-LF]As COO, Engle will combine operations and talent development, while focusing on motivating and leading a high-performance team to accommodate the rapid growth, services, and innovation at Sonora Quest.
Rejenevie™ Therapeutics announced the commencement of the company's Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration treatments targeting age-related diseases.[CR-LF]Upon arrival at the Okyanos Center, the restored stem cells are delivered back into the patient through intravenous infusion in a process lasting approximately one hour. After the patient is discharged and returns home, he or she receives periodic blood testing over a 12-month period using a kit developed with global diagnostics company Quest Diagnostics to ensure safety and to determine the therapy's effectiveness.
Quest Diagnostics, a leading provider of diagnostic information services, today announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, the largest precision medicine trial of its kind. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Tumor gene testing by a designated lab is the only pathway for patients to enroll.